Risk assessment and risk-based therapeutic strategies in febrile neutropenia

Current Opinion in Infectious Diseases

Volumn 14, Issue 4, 2001, Pages 415-422

  Kern, Winfried V ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT;

ANTIBIOTIC THERAPY; CLINICAL EXAMINATION; COMORBIDITY; DIAGNOSTIC IMAGING; FEBRILE NEUTROPENIA; HUMAN; INFECTION; INFECTION RISK; INFECTIOUS COMPLICATION; LABORATORY DIAGNOSIS; MYCOSIS; OUTPATIENT CARE; REVIEW; RISK ASSESSMENT;

EID: 0034925906     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200108000-00003     Document Type: Review

References (52)

1. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
2. Home treatment of febrile neutropenia: An empirical oral antibiotic regimen
3. Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with non-hematologic neoplasms
4. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial
5. Outpatient management of febrile neutropenia in indigent paediatric patients
6. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer
7. Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor
8. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients
9. Outpatient treatment of febrile episodes on low-risk neutropenic patients with cancer
10. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients
11. Ambulatory management of febrile episodes in low-risk neutropenic cancer patients [abstract 2235]
12. Therapy for low-risk cancer patients with fever and neutropenia: Results of a prospective, randomized trial with cost analysis
13. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever
14. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
15. Oral versus intravenous empiric therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
16. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: Randomized prospective trial
17. Domiciliary treatment of febrile episodes in cancer patients: A prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment
18. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients
19. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule
20. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia
21. Ceftriaxone in the outpatient treatment of cancer patients with fever and neutropenia
22. Safety and costs of treating neutropenic fever in an outpatient setting
23. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer
24. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule
25. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients
26. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia
27. Predicting the risk of bacteremia in children with fever and neutropenia
28. Outpatient management of febrile neutropenia according to a prediction rule
29. Vancomycin added to empirical combination therapy for fever in granulocytopenic cancer patients
30. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy
31. Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer
32. Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer
33. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia
34. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients
35. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: A prospective, observational study
36. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes
37. Double-blind, randomized, clinical trial comparing monotherapy with piperacillin-tazobactam vs. piperacillin-tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients
38. Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc-gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia
39. Prediction of gram-negative bacteremia in febrile neutropenic cancer patients by interleukin-8 serum levels: Targeting empirical mono- versus combination therapy
40. C-reactive protein and fever in neutropenic patients
41. Procalcitonin does not discriminate infection from inflammation after allogeneic bone marrow transplantation
42. Procalcitonin: A diagnostic marker of bacterial infection in neutropenic cancer patients with fever?
43. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications
44. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer
45. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
46. Empiric antifungal therapy in febrile granulocytopenic patients
47. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy
48. Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: Implications for the management of febrile neutropenia
49. Serial detection of aspergillus antigenemia in neutropenic patients at risk of invasive pulmonary aspergillosis: Results of a prospective multicenter study
50. Oral administration of cefixime to lower risk febrile neutropenic children with cancer
51. Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer
52. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever